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Materials:  
Fmoc amino acids were purchased from Anaspec and AAPPTec and used as received.  TentaGel 
S-NH2 resin (diameter 90 µm, capacity 0.28 mmol/g) was obtained from Anaspec and utilized for 
OBOC library construction. Biotin NovaTag™ resin, Biotin – PEG NovaTag™ resin, Fmoc – NH 
- (PEG)5 - OH were obtained from AAPPTec, Inc. and used for synthesis of biotinylated peptides. 
Sieber amide resin (capacity 0.3-0.6 mmol/g) purchased from Anaspec was used for synthesis of 
protected peptides. NMP (1-methyl-2 -pyrrolidinone), HATU ((2-(7-Aza-1H-benzotriazole-1-yl)-
1,1,3,3-tetramethylammonium hexafluorophosphate) and DIEA (N,N′-diisopropylethylamine) 
used in peptide synthesis were bought from EMD Chemicals, Inc., ChemPep and Sigma-Aldrich 
respectively. DMF (N,N′-dimethylformamide), piperidine, TFA (trifluoroacetic acid, 98% min. 
titration), and TES (triethylsilane) were purchased from Sigma-Aldrich. 5-Azido-pentanoic acid 
was purchased from Bachem Americas, Inc. BCIP (5-Bromo-4-chloro-3-indolyl phosphate) was 
purchased from Promega.  
  Active Akt2 (with N terminal His6 tag) was purchased from Abcam. GST-tagged PfLDH, 
PvLDH and Pf HRP2 were purchased from CTK Biotech. GST-tagged hLDH was purchased from 
Abnova. Mouse anti biotin antibody conjugated to Alkaline Phosphatase used in screens was 
purchased from Sigma Aldrich. Anti His6 mouse antibody, goat anti mouse IgG - Alkaline 
Phosphatase conjugate used in screens were purchased from Abcam.  HRP conjugated Anti-GST 
antibody was purchased from Abcam. 
Solid phase peptide synthesis:  
General	  protocol: Peptides were synthesized on Rink Amide MBHA, Biotin Novatag, Biotin PEG 
Novatag and Sieber Amide resin either manually or on the Titan 357 Automatic Peptide 
Synthesizer (AAPPTec, Louisville, KY). Amino acid solutions in NMP (2 equivalents), with 2 
equivalents of HATU and 6 equivalents of DIEA were used for the amino acid coupling reaction. 
For removal of Nα-Fmoc protecting groups, a solution of 20% piperidine in DMF was used.  
Cleavage	  of	  side	  chain	  deprotected	  peptide: The peptides were synthesized on the Rink Amide 
MBHA, Biotin Novatag or Biotin PEG Novatag resin.  The resin was treated with a TFA cleavage 
solution (TFA: TES: ddH2O; 95:2.5:2.5) for two hours at room temperature.  The cleavage solution 
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was filtered through a Gooch filter crucible and added dropwise to an ice cooled solution of diethyl 
ether.  
High	   Pressure	   Liquid	   Chromatography	   (HPLC)	   purification	   of	   peptides: All the peptides were 
purified using a gradient of double distilled water and HPLC grade acetonitrile, both containing 
0.1% TFA, on the RP-HPLC (Beckman Coulter System Gold 126 Solvent Module and 168 
Detector) using a C18 reversed phase semi-preparative column (Phenomenex Luna 10 µm, 250 × 
10 mm).   
Protocol	   for	   on	  bead	   cyclization	  by	   copper	   (Cu)	   catalyzed	  azide	   alkyne	   cycloaddition	   (CuAAC)	  
“click”	  reaction: On bead linear peptide with L-azidolysine at N terminal and L-propargylglycine 
at C terminal was cyclized by treating with 2.5 quivalents of CuI (Sigma) and 5.0 equivalents of 
ascorbic acid (Sigma), in a solution of 20% piperidine in DMF. The reaction was performed 
overnight at room temperature. The excess copper was removed from the resin by washing 
extensively with a Cu chelating solution (5% (w/v) sodium diethyldithiocarbamate, 5% (v/v) DIEA 
in DMF). 
Protocol	  for	  on	  bead	  Ru(IV)	  catalyzed	  Ring-­‐Closing	  Metathesis	  reaction	  (RCM)	  reaction:	  On resin 
linear peptide was swelled for 30 minutes in anhydrous dichloroethane (DCE) at room temperature 
in inert atmosphere. 10 mL of 10 mM 1st generation Grubb’s catalyst in DCE was added to the 
swelled resin and the reaction was allowed to proceed for 6 hours. The solution was drained and 
the reaction with the catalyst was repeated for 6 hours. Then the library was washed with 
dichloroethane (DCE) five times for five minutes each. Following the RCM reaction, excess 
unreacted catalyst adsorbed to the beads were removed by washing with 5 % triphenyl phosphine 
in DCM, five times for ten minutes each, followed by washes with 5 % oxine solutions in DMF, 
five times for ten minutes each. 
Peptide library Synthesis:   
Randomized OBOC libraries of peptides were synthesized using the Titan 357 Automated Peptide 
Synthesizer (AAPPTec) on 90 µm polyethylene glycol-grafted polystyrene beads (TentaGel S-
NH2, 0.28 mmol/g, 2.86 x 106 beads/g). Two comprehensive hepta/octameric linear peptide 
libraries Pra-X1X2X3X4X5-L-Az4 (Pra = L-propargylglycine, Xi = 18 natural amino acids except 
Cys and Met, Az4 = L-azidolysine) and R8-GX1X2X3X4X5-S5-linker-TG, (where R8 =(R)-2-(7’-
octenyl)alanine, Xi = 18 natural amino acids except Cys and Met, S5 = (S)-2-(4’-pentenyl)alanine) 
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were synthesized on Tentagel-SNH2 resin using standard SPPS library synthesis method. Each 
library was synthesized at a 10-fold excess to ensure adequate representation of each library 
element. The CuAAC cyclization and RCM cyclization of the libraries are done as described 
before. After washes to remove the adsorbed metal, the libraries were washed with 
dimethylformamide (DMF), methanol and dichloromethane (DCM) and dried. Random beads were 
picked from the library to be sequenced. The rest of the library was stored in N-methyl-2-
pyrrolidone (NMP).  Before screening the libraries with the SynEps, Az4 or Pra were coupled on 
the N terminal of the cyclic peptide library following standard Fmoc based SPPS methods. 
Screening cyclic OBOC library with peptide epitope: 
500 mg of resin from the library is swelled and shaken overnight in binding buffer (25 mM trisCl, 
pH = 7.5, 150 mM NaCl, 0.1% BSA, 0.05% Tween20) at room temperature. Beads were incubated 
with a solution of 10 µM of the scrambled or the off-target peptide for 6 hours at room temperature 
in binding buffer. The beads were washed three times, for fifteen minutes each, with the binding 
buffer. They were then treated for 1 hour in cold room with a 1:1000 dilution of mouse 
monoclonal Anti-biotin antibody conjugated with Alkaline Phosphatase (mAb-AP) in screening 
buffer. Following the screen, the beads were successively washed three times with binding buffer, 
followed by three washes with each of the following buffers: 25 mM trisCl, pH = 7.5, 150 mM 
NaCl, 0.05% Tween20 (TBST); 25 mM tris.HCl, pH = 7.5, 150 mM NaCl (TBS); 100 mM 
Tris.HCl, pH 9.0, 150 mM NaCl, 1 mM MgCl2) (AP buffer). The library was treated with a 5-
bromo-4-chloro-3-indolyl phosphate (BCIP) solution (33 µL BCIP in 10 mL AP buffer) for fifteen 
minutes. The AP reaction was stopped using 0.1 M HCl, which denatures AP protein. Blue 
background hits were removed from clear ones using a pipette. Clear beads were combined and 
transferred to a peptide synthesis vessel. The beads were treated with 7.5 M guanidine-HCl pH = 
2, a protein denaturant, for 2 hours at room temperature. Afterwards, the library was washed with 
deionized water and treated with DMF to decolorize the blue beads. Following a wash with DCM, 
the clear beads were dried, then shaken overnight in binding buffer. 
The beads were screened with a 5 µM solution of the target peptide in binding buffer for 6 
hours at room temperature. Following washes with the binding buffer, the beads were treated with 
a 1:1000 solution of mAb-AP. The same procedure as in the prescreening was conducted to obtain 
blue click hits. The beads were manually picked, washed with 7.5 M guanidium hydrochloride (pH 
2) and water, decolorized with DMF treatment followed by water washes, and sequenced using the 
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Edman Sequencer. 
ELISA of cyclic peptides against full-length proteins: 
These assays were conducted to test the binding of the various ligands to the target protein. The 
target protein were GST-tagged. 1-2 µM of the biotin conjugated peptide ligands were first 
immobilized onto Neutravidin ELISA plates (Pierce) for 2 hours at room temperature in binding 
buffer (TBST with 0.1% BSA).  A PEG5-biotin was used as the no-ligand blank, as the GST 
proteins has significant background binding to the blank Neutravidin plate.  The plates were then 
blocked with 3% BSA or 5% milk overnight.  The plates were then treated with pM to µM 
concentration of the target protein. For a single point ELISA, a single concentration of the protein 
was used in triplicate wells, while for obtaining an EC50 curve, a concentration series of the protein 
was used. The proteins were incubated for three hours at 4°C, then washed three times with 
binding buffer.  The protein was then treated with a 1:2000 dilution of the anti-GST mouse mAb 
(Fisher) in binding buffer for one hour, washed three times with TBST, once with TBS, and 
developed with TMB substrate (KPL) for five to ten minutes.  The absorbances of samples at 450 
nm wavelength were measured using a spectrophotometer. The absorbance measured at 450 nm 
for Peg5-biotin for the protein concentration series are subtracted from the A450 values of those 
for each ligand to obtain final values. Error bars indicate one standard deviation above and below. 
Fluorescence Polarization Assays: 
PCC reagents 1 and 2 were tagged with fluorescein by coupling fluorescein isothiocyanate to a 
lysine side chain at the C termini of the peptides. Solutions of 1 and 2 and the protein dilutions 
were made TBST. 15 nM of 1 or 31 nM of 2 were added to each well on a Costar black 96 well 
plate and titrated with a concentration series of PfLDH and PfHRP2 respectively. Each 
measurement was done in triplicate. The plate was kept overnight at room temperature with 
shaking, and the fluorescence polarization read on a Flexstation3 plate reader. Using GraphPad 
Prism, the curves were fitted to one site specific binding with Hill slope. 
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Figure S1: EC50 and mass spectroscopic characterization of PCC 1, with sequence 
Cy(HWSAN-click).  
A. Sandwich ELISA of the ligand Cy(HWSAN-click) against rPfLDH protein yields an EC50 
value of 23.39 ±6.37 nM. The ELISA is performed as described in the protocol above, 
immobilizing biotinylated 1, treating with GST-tagged rPfLDH, and probing with anti-GST mouse 
antibody –HRP. B. Electron Spray Ionization (ESI) Mass spectroscopy characterization of 1. 
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Figure S2: Molecular structure, EC50 and mass spectroscopic characterization of linear 
peptide hevwh.   
A. Molecular structure of hevwh linear peptide. B.  Sandwich ELISA of the ligand against  
rPfLDH protein yields an EC50 value of 1.7 µM ± 0.8 µM. The ELISA is performed as described 
in the protocol above, immobilizing biotinylated hevwh, then treating with GST-tagged rPfLDH, 
probing with anti-GST mouse antibody–HRP, and developing with TMB substrate. C. Maldi TOF 
mass spectroscopy characterization of hevwh. 
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Figure S3: EC50, mass spectroscopic characterization, and selectivity in serum of 2, with 
sequence Cy(GSTEWL-rcm). 
 A. Sandwich ELISA of the ligand 2 against rPfHRP2 protein yields an EC50 value of 20.46 ± 2.04 
nM. The ELISA is performed as described in the protocol above, immobilizing Cy(GSTEWL-
rcm), then treating with GST-tagged rPfHRP2, then probing with anti-GST mouse antibody–HRP. 
B. ESI mass spectroscopy characterization of 2. C. Binding of cyclic peptide Cy(GSTEWL-rcm) 
to 25 nM PfHRP2 in buffer and in 1% serum. The biotinylated peptide is immobilized on a 
streptavidin 96 well plate and treated with 25 nM GST tagged PfHRP2 or 25 nM GST protein in 
buffer or in 1% serum. The plate is then treated sequentially with goat polyclonal anti-GST-HRP 
antibody and and TMB substrate to detect binding of the ligands to the epitope. The signal has a 
small decrease (16%), which implies a low cross reactivity with common serum proteins. The 16% 
drop is likely because of the very low concentration of protein.  The protein is kept at a low 
concentration so as to portray reasonably realistic assay conditions. 
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Figure S4: Molecular structure, EC50 and mass spectroscopic characterization of Cy(Y-4F-
Phe-YRV-click).  
A. Molecular structure of Cy(Y-4F-Phe-YRV-click). B. Sandwich ELISA of the ligand against 
PfHRP2 protein yields an EC50 value of 538 pM. The ELISA is performed by immobilizing the 
ligand on a streptavidin plate, treating with GST-tagged rPfHRP2, and probing with anti-GST 
mouse antibody –HRP. C. Maldi TOF mass spectroscopy characterization of Cy(Y-4F-Phe-YRV-
click). 
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Figure S5: Molecular structure, EC50 and mass spectroscopic characterization of 
Cy(YKYYR -click).  
A. Molecular structure of Cy(YKYYR-click). B. Sandwich ELISA of the ligand against rPfHRP2 
protein yields an EC50 value of 218 nM ± 44 nM. The ELISA is performed as described in the 
protocol above, immobilizing Cy(YKYYR-click), treating with a concentration series of GST-
tagged rPfHRP2, then probing with anti-GST mouse antibody – HRP. C. Maldi TOF mass 
spectroscopy characterization of Cy(YKYYR-click). 
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Figure S6: Molecular structure, EC50 and mass spectroscopic characterization of 
Cy(RYKHY -click).   
A. Molecular structure of Cy(RYKHY-click). B. Sandwich ELISA of the ligand against protein 
yields an EC50 value of 4 nM. The ELISA is performed as described in the protocol above, 
immobilizing Cy(YKYYR-click), treating with a concentration series of GST-tagged rPfHRP2, 
then probing with anti-GST mouse antibody –HRP. C. Maldi TOF mass spectroscopy 
characterization of Cy(RYKHY-click). 
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Figure S7: Molecular structure, EC50, selectivity assay and mass spectroscopic 
characterization of Cy(DARNI - click).  
 A. Molecular structure of Cy(DARNI-click). B. Sandwich ELISA of the immobilized ligand 
against L1R protein, an envelope protein on the Vaccinia virus, yields a EC50 value of 875 nM. 
The biotinylated ligand is immobilized on a SA plate, treated with varying concentrations of GST 
tagged L1R protein, and probed with anti-GST mouse antibody –HRP. QuantaRed™ Enhanced 
Chemifluorescent HRP Substrate is used to quantify the interaction. C. The ligand is immobilized 
on SA beads and used to immuno-precipitate 500 nM L1R protein in buffer (TBST with 0.1% 
BSA) and 500 nM L1R protein spiked into 1% human serum in buffer. BSA is used as a loading 
control. D. Maldi TOF mass spectroscopy characterization of Cy(DARNI-click). 
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Figure S8: Molecular structure, EC50, selectivity assay and mass spectroscopic 
characterization of Cy(RRATS -click).   
 A. Molecular structure of Cy(RRATS-click). B. Sandwich ELISA of the ligand against IL-17F 
protein yields an EC50 value of 66 nM. The biotinylated ligand is immobilized on a SA plate, 
treated with varying concentrations of GST tagged L1R protein, and probed with anti-GST mouse 
antibody –HRP. QuantaRed™ Enhanced Chemifluorescent HRP Substrate is used to quantify the 
interaction. C. The immobilized biotinylated ligand is treated with 200 nM or 50 nM GST tagged 
IL-17F and IL-17A proteins and probed with anti-GST mouse antibody –HRP. QuantaRed™ 
Enhanced Chemifluorescent HRP Substrate is used to quantify the interaction. The ELISA 
demonstrates preferential binding to IL-17F. D. Maldi TOF mass spectrometry characterization of 
Cy(RRATS-click). 
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Figure S9:  Molecular structure, mass spectroscopic characterization, EC50 and selectivity 
assay of Cy(YYTYT-click).   
 A. Molecular structure of Cy(YYTYT-click). B. Sandwich ELISA of the immobilized ligand 
against Akt2 protein. The Cy(YYTYT-click) peptide is immobilized on a streptavidin plate and 
treated with a concentration series of His6 tagged Akt2 protein. The binding is detected by treating 
with mouse anti-His antibody and anti-mouse antibody-HRP. C. ESI mass spectroscopy 
characterization of Cy(YYTYT-click). D. Point ELISA of Cy(YYTYT-click) against target 
phospho-peptide and its non-phosphorylated analog demonstrates preferential binding to phospho-
epitope. 1.25 µM Cy(YYTYT-click) peptide is immobilized on a streptavidin plate and treated 
with 2.5 µM  His6 tagged phosphorylated and non-phosphorylated epitope peptides. The binding is 
detected by treating with mouse anti-His6 antibody, anti-mouse antibody-HRP and TMB substrate. 
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Figure S10: Selectivity of Cy(NYRWL-click) for Botulinum neurotoxin serotype A.  
Binding of Cyclic peptide (Cy(NYRWL-click) to Botulinum neurotoxin serotype A light chain 
protein in buffer, 1% serum and 5% serum. The biotinylated peptide is immobilized on a 
streptavidin 96 well plate and treated with 500 nM GST tagged Botulinum neurotoxin serotype A 
light chain protein in buffer, in 1% serum and in 5% serum. The plate is then treated with anti-
GST-HRP antibody and and TMB substrate to detect binding of the ligands to the epitope.  The 
binding efficiency has minimal reduction, indicating no significant off-target interactions with 
common serum proteins occur. 
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Figure S11: IR spectra of the linear peptide L-Pra-VFAKV-L-Az4 and the corresponding on 
bead CuAAC cyclized peptide Cy(VFAKVTz4).  
The linear peptide L-Pra-VFAKV-L-Az4 is synthesized on Rink Amide MBHA resin on a 200 mg 
scale. 100 mg of the peptide is left uncyclized, while 100 mgs are cyclized according to the 
protocol for on bead cyclization by copper (Cu) catalyzed azide alkyne cycloaddition (CuAAC) 
“click” reaction. Both peptides are cleaved, lyophilized and analyzed by solid state IR 
spectroscopy.	   The uncyclized peptide L-Pra-VFAKV-L-Az4 at bottom has a characteristic 
asymmetric NNN stretch (~ 2100 cm-1), while the isobaric cyclized peptide Cy(VFAKVTz4) at the 
top does not, due to triazole formation. 
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Figure S12: CuAAC cyclization of a peptide on bead yields mainly monomer, with small 
amounts of dimer and trimer formation. 
Semi-preparative HPLC of cleaved crude precipitate for the peptide Cy(HWSAN-click) 
synthesized on resin yields a major peak of monomer cycle, and minor amounts of the dimeric and 
trimeric cyclic products. The later peaks in the HPLC corresponds to the catalyst used in the RCM 
reaction. 
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Table S1: Anti-screen conditions for different epitopes. 
 
Epitope Antiscreen condition 
LISDAELEAIFD-Az4 – PEG5- Biotin (amino acids 218-
229 of PfLDH) 
Screen with DDIAILEEFALSAz4-Peg5-Biotin 
(scrambled epitope), anti-biotin mAb-AP, BCIP 
AHHATDAHHAAAHHEAATHC -Pra – PEG5- Biotin 
(C terminal of  rPfHRP2) 
Screen with 
MVSFSKNKVLSAAVFASVLLLDNNNS A – Pra - 
Peg – Biotin (N terminal fragment of rPfHRP2), Pra 
FNNNLCSKNAKGLNLN KRLLHETQAHVDD – 
Peg –Biotin (N terminal fragment of  rPfHRP2), anti-
biotin mAb-AP, BCIP 
Biotin - PEG5 – AHHAADAHHA – Pra  
 (type 2 repeat of rPfHRP2) 
Screen with Biotin -PEG5 – AAAHHEATHCL – Pra 
(C terminal of rPfHRP2), anti-biotin mAb-AP, 
BCIP/NBT 
Pra-AHHAHHAAD-PEG5-Biotin 
(variant of type 2 repeat of rPfHRP2) 
Screen with Biotin –PEG5 – AAAHHEATHCL – Pra  
(C terminal of rPfHRP2), anti-biotin mAb-AP, 
BCIP/NBT 
Biotin-PEG5- LHETQAHVDD 
-Pra (N terminal repeat of rPfHRP2) 
Screen with Biotin –PEG5 – AAAHHEATHCL – Pra  
(C terminal of rPfHRP2), anti-biotin mAb-AP, 
BCIP/NBT 
Biotin-W-PEG5-GVEQV-Pra-ELQLN 
(amino acids 297-308 of PfLDH) 
Screen with Biotin-W-PEG5-GISDLVKVTLT 
(corresponding hLDH epitope), anti-biotin mAb-AP, 
BCIP/NBT 
KALMQLTTKATTQIA-Pra-PKQVAGTGVQ (L1R) anti-biotin mAb-AP, BCIP/NBT 
Biotin-PEG3-FFQKPES[Az4]PPVPGGS (amino acids 
 40-54 of IL-17F) 
Additional screens with hits after screen: Screen with 
full-length His6 tagged IL-17-F, detect with anti-his6 
antibody-alkaline phosphatase, BCIP/NBT; Screen 
with full-length His6 tagged IL-17-F in 2% serum, 
detect with anti-his6 antibody-alkaline phosphatase, 
BCIP/NBT. 
Biotin-  PEG5 - 
ITPPDRYDSLGLLELQRTHFPQF(pS)YSASIRE (Akt2 
450-481) 
Screen with Biotin- PEG5 – ITPPDRYDSLGLLEL-
QRTHYFFASQPS- SIRE (scrambled and non-
phosphorylated in the hydrophobic motif), anti-biotin 
mAb-AP, BCIP 
Az4-SFGHEVLNLTRN-PEG-Biotin (amino acids 166-
179 of Botulinum neurotoxin serotype A light chain) 
Screen with Az4-NGTLFNLSEVRH-PEG4-Biotin 
(scrambled epitope), anti-biotin mAb-AP, BCIP/NBT 
MSDVAIVKEGWLKKRGKY[Pra]KTWRPRYFLLKN
DG (Akt1 point mutation) 
Screen with anti-biotin mAb-AP, BCIP/NBT 
 
 22 
Figure S13: Synthesis of on bead RCM cyclized peptide library. 
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Figure S14: RCM cyclization of peptide on bead yields different products depending on the 
sequence of the amino acids and the position of PEG linker and biotin tag.   
A. Semi-preparative HPLC trace for crude peptides Cy(GHWSAN-rcm)-Peg5-biotin and 
Cy(GSTEWL-rcm)-Peg5-Biotin after RCM reaction on resin. The different peaks correspond to the 
mass of monomeric cycle. The shallow gradient on the HPLC results in high resolution of peaks.  
B. Semi-preparative HPLC trace for purification of crude peptide Cy(GTESVA-rcm) -Peg5-biotin 
after RCM reaction on resin. The major peaks have mass corresponding to the dimeric cycle. In 
this reaction, different dimerization reactions can occur, which could elute as different peaks. The 
monomer is formed in trace amounts. C. Semi-preparative HPLC traces for purification of the 
peptide with same amino acid sequence Cy(GWNVDL), but with the Peg5 linker and biotin tag 
either on C or N terminus. The major peaks correspond to the dimeric and monomeric cyclic 
peptide respectively. So the same amino sequence cyclized by RCM reaction on bead yields 
monomer or dimer depending on position of the PEG linker and biotin tag.  
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Figure S15: Representative Edman traces from sequencing of a CuAAC reaction cyclized 
peptide on bead.  
The first cycle on the Edman sequencer runs the amino acid standards. The second cycle contains 
the azide appended after cyclization. In the third Edman cycle, the cyclic amide bond is broken, 
but the amino acid is still attached to the bead, resulting in a blank circle. The rest of the peptide 
sequences normally, similarly to a linear peptide. All the cycles have diphenylthiourea (dptu) as an 
internal standard. 
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Figure S16: Representative Edman traces from sequencing of a RCM cyclized peptide on 
bead. 
The first cycle on the Edman sequencer runs the amino acid standards. The second cycle contains 
the azide appended after cyclization. In the third Edman cycle, the cyclic peptidic bond is broken, 
but the amino acid is still attached to the bead, resulting in a blank circle. The rest of the peptide 
sequences normally, similarly to a linear peptide. All the cycles have diphenylthiourea (dptu) as an 
internal standard. 
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Table S2: Hit sequences obtained from epitope screen (amino acids 218-230) of PfLDH. 
 
 
Pra no peak X1 X2 X3 X4 X5 
Pra - R G G I L 
Pra - K K I H L 
Pra - P L K K G 
Pra - L K T G Q/T 
Pra - H W S A N 
 
 
 
 
Figure S17: Epitope selectivity of PfLDH ligands obtained from screen for the unmodified 
target epitope of PfLDH.  
200 nM epitope (amino acids 218-230 of PfLDH) conjugated to BSA is immobilized on a nunc 
plate and treated with 150 nM biotin tagged ligands. The plate is then treated with an anti-biotin 
antibody-HRP conjugate and TMB substrate to detect binding of the ligands to the epitope.  
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Figure S18: Single point ELISA depicting binding of hit peptides obtained from screen 
against SynEp of PfLDH to the PfLDH protein.  
1.25 µM solutions of  different biotinylated ligands are immobilized in the plate and treated with 
100 nM GST tagged PfLDH protein. Binding is detected by treatment with anti-GST antibody 
conjugated with HRP and subsequent treatment with TMB substrate. The absorbance measured at 
450 nm for no protein and no peptide controls are subtracted from the A450 values for each ligand. 
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Table S3: Hit sequences obtained from epitope screen of Pf HRP2. 
 
 
Az4 No 
peak 
G X1 X2 X3 X4 X5 
Az4 - G I F A V T 
Az4 - G I V G A P 
Az4 - G N W P A A 
Az4 - G F/W N V D L 
Az4 - G S T E W L 
Az4 - G T E S V A 
Az4 - G T I T I Y 
Az4 - G T A V N A 
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Figure S19: Single point ELISA depicting binding of hit peptides obtained in screen against 
SynEp of PfHRP2 to the PfHRP2 protein.  
1.25 µM solutions  of different biotinylated ligands are immobilized in the plate and treated with 
20 nM GST tagged PfHRP2 protein. Binding is detected by treatment with anti-GST antibody 
conjugated with HRP and subsequent treatment with TMB substrate. The absorbance measured at 
450 nm for no protein and no peptide controls are subtracted from the A450 values for each ligand. 
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Figure S20: Selection of the best PCC against PfHRP2 from the hit sequences that exhibit 
high binding to the PfHRP2 protein. 
Sandwich ELISA of the biotinylated ligands Cy(GIVGAP-rcm), Cy(GNWPAA-rcm) and 
Cy(GSTEWL-rcm) against PfHRP2 protein yields an EC50 values of 27.22 nM, 28.05 nM and 20.6 
nM respectively. The ELISA is performed as described in the sandwich ELISA protocol above. 
The ligand Cy(GSTEWL-rcm) with the lowest EC50 value is chosen as the best PCC for PfHRP2. 
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Figure S21: Structure and mass spectroscopic characterization of fluorescein labeled ligands 
1 and 2.  
A. Molecular structure of fluorescein conjugated 1. B. ESI mass spectra of fluorescein conjugated 
1. Calculated mass:1378.5; Observed mass: 1378.9. C. Molecular structure of fluorescein 
conjugated 2. Calculated mass:1500.7; Observed mass: 1502.1. D. ESI mass spectra of fluorescein 
conjugated 2. 
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